Are Nanoparticles the Answer to the Question: Is it Working? An Interview with MRA Young Investigator, Dr. Ashish Kulkarni
When we think about cancer researchers, we don’t always think of engineers. Dr. Ashish Kulkarni proves that maybe, we should. His pioneering work as a chemical engineer is helping us answer the critical, yet difficult to answer question that is at the forefront of every patient’s mind as they start treatment: ‘is it working?’
‘Practice Changing’ Results Hint at New Adjuvant Therapy Treatment Options
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 September 2017 In Treatment
Adjuvant treatment is used in addition to tumor removal e.g. via surgery or radiotherapy to help delay or prevent the recurrence of melanoma. It is often recommended for high-risk melanoma (defined as melanoma deeper or thicker than 4mm thick at the primary site or involves nearby lymph nodes). Approved adjuvant therapies in melanoma include interferon and, more recently, ipilimumab. But neither of these approaches is wholly satisfying since relatively few patients appear to benefit and side-effects are a major factor.
Melanoma Survivor and Pro Baseball Hall of Famer Mike Schmidt Shares His “Game Plan” for Battling Cancer
Mike Schmidt, member of the Baseball Hall of Fame, is considered to be the greatest third baseman of all-time. As a professional athlete, he always felt invincible, but in 2013 a melanoma diagnosis threw him a curveball that he wasn’t prepared for.
Bristol-Myers Squibb Funds Two MRA Young Investigator Awards in Immuno-Oncology
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 6 September 2017 In Allies & Partnerships, Science, Treatment
MRA is pleased to announce Bristol-Myers Squibb (BMS) has provided generous support for two Young Investigator Awards from our 2016-2017 grant cycle. The recipients of the Bristol-Myers Squibb - MRA Young Investigator Award are Dr. Erica Stone of The Wistar Institute and Dr. Manuel Valiente of Fundación Centro Nacional de Investigaciones Oncológicas Carlos III. MRA’s independent panel of academic experts selected these two immuno-oncology research programs to receive funding in 2017.
A Mother’s Perspective: New Options for Pediatric Melanoma
When Cheryl Trocke’s nine-year old son Graham was diagnosed with melanoma four years ago, she quickly learned that when it comes to kids, there were no great treatment options and that care can vary greatly based on where your child is treated. After surgically removing the primary tumor, Graham’s doctors suggested a treatment plan of ‘wait and see.’
Measuring Progress: Skin Cancer Prevention in the United States
On July 29 2014, Dr. Boris Lushniak, the then acting U.S. Surgeon General at, issued a landmark call to action when he declared skin cancer as a major public health problem. He called on everyone, from government agencies to community-based organizations to schools to come together to increase awareness of skin cancer and ways to reduce risk. Since the Call to Action, The Centers for Disease Control and Prevention (CDC) has released an annual report each year documenting progress, celebrating success, and identifying areas where improvement is needed. The key areas of the Call to Action and the update from the CDC 2017 Progress Report are highlighted below.
Doubling Down: Brandon Barniea Bets Big on Combination Therapy
Brandon Barniea didn’t believe he needed to visit doctors. The athletic 35-year-old had always been healthy – even when his wife and two kids were sick at home with the flu, he would miraculously avoid falling ill. So, when he found what felt like “beads” in his neck, reality came crashing in; following a biopsy, he was diagnosed first with stage III melanoma in August 2015 and later that year it progressed to stage IV.
L’Oréal Paris USA-MRA Team Scientists shed light on how melanoma spreads
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 29 August 2017 In Allies & Partnerships, Science, Treatment
MRA is extremely proud of the 289 investigators we have funded over the last decade and the exciting advances they have made toward ending suffering and death due to melanoma. While we can never highlight all of them at one time, we’re excited in this blog to highlight the work of the L’Oreal Paris USA sponsored MRA Team award.
MRA Announces its Tenth Annual Request for Proposals
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 14 August 2017 In News, Science, Treatment
MRA is pleased to announce our 2017/18 Request for Proposals (RFP). As in prior years, MRA seeks high-impact pre-clinical, translational, and early clinical research that has the potential to lead to near-term impact in melanoma prevention, detection, diagnosis, staging, and treatment.
Why so much excitement about CAR-T cells?
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 18 July 2017 In News, Science, Treatment
July 12, 2017, marked a historic day for medicine and for the US Food and Drug Administration (FDA) when an expert advisory committee to the FDA unanimously endorsed the first ever genetically engineered, cell-based therapy for use in patients.